<DOC>
	<DOCNO>NCT00185068</DOCNO>
	<brief_summary>Effect increase dos olmesartan medoxomil olmesartan medoxomil/hydrochlorothiazide blood pressure patient hypertension</brief_summary>
	<brief_title>An Examination Safety Blood Pressure Lowering Effect Increasing Doses Benicar® Benicar® HCT Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>1 . 18 year age . 2 . Patients stage II systolic hypertension 3 . If female , must negative serum pregnancy test screen either postmenopausal , hysterectomy tubal ligation least 6 month consent childbearing potential , must practice approve measure birth control throughout study . 1 . Hypertensive encephalopathy , stroke transient ischemic attack ( TIA ) within past 6 month . 2 . History myocardial infarction , percutaneous transluminal coronary revascularization , coronary artery bypass graft , and/or unstable angina pectoris within past 6 month . 3 . Severe hypertension ( DBP great equal 110 mm Hg SBP &gt; 200 mm Hg ) . 4 . History secondary hypertension include renal disease , phaeochromocytoma , Cushing 's disease . 5 . Type I diabetes mellitus . 6 . Evidence symptomatic resting bradycardia , congestive heart failure , hemodynamically significant cardiac valvular disease . 7 . Presence heart block great first degree sinoatrial block , WolffParkinsonWhite Syndrome , Sick Sinus Syndrome , Atrial fibrillation , Atrial Flutter . 8 . Laboratory test value consider clinically significant investigator . 9 . Evidence liver disease indicate SGOT SGPT and/or total bilirubin &gt; 3 time upper limit normal . 10 . Pregnant lactating female . 11 . Patients malignancy past 5 year exclude squamous cell basal cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Systolic hypertension , Angiotensin receptor blocker</keyword>
</DOC>